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Abstract
Background: Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are
currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and
acute lymphocytic leukaemia (ALL).
Methods: We investigated whether expression ratios of immunoproteasome to constitutive proteasome in
leukaemic cells correlated with response to bortezomib-containing re-induction chemotherapy in patients with
relapsed and refractory acute leukaemia, enrolled in two Children’s Oncology Group phase 2 trials of bortezomib for
ALL (COG-AALL07P1) and AML (COG-AAML07P1). Expression of proteasome subunits was examined in 72 patient
samples (ALL n = 60, AML n = 12) obtained before start of therapy. Statistical significance between groups was
determined by Mann-Whitney U test.
Results: Ratios of immunoproteasome to constitutive proteasome subunit expression were significantly higher in
pre-B ALL cells than in AML cells for both β5i/β5 and β1i/β1 subunits (p = 0.004 and p < 0.001). These ratios
correlated with therapy response in AML patients; β1i/β1 ratios were significantly higher (p = 0.028) between
patients who did (n = 4) and did not reach complete remission (CR) (n = 8), although for β5i/β5 ratios, this did not
reach significance. For ALL patients, the subunit ratios were also higher for patients who showed a good early
response to therapy but this relation was not statistically significant. Overall, for this study, the patients were treated
with combination therapy, so response was not only attributed to proteasome inhibition. Moreover, the leukaemic
blast cells were not purified for these samples.
Conclusions: These first ex vivo results encourage further studies into relative proteasome subunit expression to
improve proteasome inhibition-containing therapy and as a potential indicator of bortezomib response in acute
leukaemia.
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Background
The survival of paediatric patients with leukaemia has
greatly improved in recent decades. However, 10–
30 % of patients still relapse, and outcome after re-
lapse remains poor, with remission rates as low as
10–40 % for poor prognostic subtypes [1, 2]. Hence,
there is a need for improvement in therapeutic op-
tions for these patients. Based on the proven clinical
activity in multiple myeloma (MM) [3] and mantle
cell lymphoma [4], as well as encouraging preclinical
data from our lab [5] and the Paediatric Preclinical
Testing Program [6], the proteasome inhibitor (PI)
bortezomib is currently undergoing clinical evaluation
in paediatric leukaemia [7, 8].
Proteasomes are large, multi-subunit complexes lo-
cated in both the cytosol and nucleus and are respon-
sible for the degradation of the majority of intracellular
proteins. In addition to constitutive proteasomes (β1 +
β2 + β5), the immunoproteasome (β1i + β2i + β5i) rep-
resents a proteasome variant that is predominantly
expressed in haematopoietic cells [9–11]. The immuno-
proteasomes produce peptides similar to constitutive
proteasomes. Although the exact role of the immuno-
proteasome has yet to be defined, the peptide fragments
produced by the immunoproteasome are thought to play
a role in antigen presentation to MHC class I antigens
(reviewed in [12]). Disruption of proteasome activity re-
sults in rapid accumulation of toxic regulatory proteins
in the cell that results in endoplasmic reticulum (ER)
stress and activates the unfolded protein response
(UPR), which blocks protein translation and initiates al-
ternative degradation pathways in stress situations [13].
Another mechanism of action of bortezomib is thought
to inhibit NF-kB chemotherapy-induced pro-survival
pathways in leukaemic blasts by blocking the proteaso-
mal degradation of NF-kB’s natural inhibitor, IkB [14].
Although bortezomib displays only modest single-
agent activity in children [15] and adults [16–18], it has
additive or synergistic interactions with cytotoxic agents
commonly used to treat acute leukaemia including glu-
cocorticoids, vincristine [5] and anthracyclines [19].
Phase 1/2 studies combining bortezomib with standard
induction/consolidation regimens have shown promising
clinical activity in both adult AML [20–22] and paediat-
ric ALL [8, 23]. However, bortezomib did not improve
complete remission (CR) rate or overall survival in a
paediatric AML cohort [7]. Thus, the clinical impact of
PI therapy in combination with cytotoxic chemotherapy
has not yet been fully assessed.
Despite the encouraging results of bortezomib in
early-phase clinical trials, primary or acquired resist-
ance to bortezomib may limit its efficacy [24, 25] and
thus identifying those patients who respond to
bortezomib-containing therapy is of great clinical
relevance. Recently, we reported that higher ratios of
immunoproteasome to constitutive proteasome pro-
tein expression in paediatric ALL and AML leukaemia
cells at diagnosis predicted ex vivo sensitivity to bor-
tezomib and other PIs [10]. The importance of sub-
unit assembly for PI sensitivity was further
investigated in leukaemia cell lines, revealing that
interferon-γ-induced upregulation of immunoprotea-
some subunit expression and concomitant downregu-
lation of constitutive subunit expression, markedly
sensitizing bortezomib-resistant cells to PIs, with the
β5i being the most important subunit involved in this
process [26].
Here, we explored whether ratios of immunoprotea-
some to constitutive proteasome protein expression cor-
relate with bortezomib response in paediatric leukaemia
patients treated with bortezomib-containing re-induction
chemotherapy. Specifically, paediatric patients with acute
leukaemia in first relapse were enrolled in two Children’s
Oncology Group (COG) phase 2 trials of bortezomib
combined with re-induction chemotherapy for paediatric
ALL (AALL07P1) or paediatric AML (AAML07P1). In
addition to (immuno) proteasome profiling, we also exam-




Pre-treatment, snap-frozen peripheral blood mononuclear
cells (PBMCs) or mononuclear cells isolated from the
bone marrow were obtained from 84 patients enrolled in
either the ALL (COG-AALL07P1; NCT00873093) or
AML (COG-AAML07P1; NCT00666588) clinical trials
between 2009 and 2013. Since no differences in overall
survival between the two randomization arms in
AAML07P1 were observed [7], no distinction was made
between AML patients receiving etoposide or idarubicin.
Informed consent was obtained from the patient or their
parent(s), and the studies have been performed according
to the Declaration of Helsinki. Assent, as appropriate,
were obtained in accordance with the US National Cancer
Institute, and the study was approved by the relevant
COG committees, CTEP and the paediatric central IRB in
accordance with institutional policies for human subjects’
research. Mononuclear cells were isolated using Ficoll
density centrifugation prior to proteasome and NF-kB
analysis. Only samples with blast percentages >20 % were
included in the analyses. Seventy-two patient samples
were available for proteasome subunit expression analysis
(60 ALL and 12 AML), and 32 patient samples (22 ALL
and 10 AML) for proteasome subunit catalytic activity.
Forty-eight patient samples (36 ALL and 12 AML) were
evaluable for NF-kB analysis. Table 1 summarizes patient
demographics.
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Protein expression/Western blotting
Antibodies to proteasome subunits β1, β2, β5, β1i
and β5i were purchased from Enzo Life Sciences
(Farmingdale, NY, USA), and the IRDye infrared-
labelled secondary antibodies were from LI-COR Bio-
sciences (Lincoln, NE, USA). In addition, anti-actin
(clone C4) was purchased from Millipore (Temecula,
CA, USA). Protein expression levels of constitutive
proteasome subunits β5 (PW-8895) and β1 (PW-
8140) and immunoproteasome subunits β5i (PW-
8845) and β1i (PW-8345) were determined by West-
ern blot analysis as previously described [10, 26, 27].
Protein bands were quantified by Odyssey software,
corrected for background, and normalized with β-
actin. Subunit expression between patient samples on
different gels was normalized using subunit expres-
sion in the leukaemic T-ALL cell line CCRF-CEM
[27].
Subunit-specific β5 and β5i proteasome catalytic activities
Subunit-specific proteasome catalytic activity of β5 (Ac-
WLA-AMC) and β5i (Ac-ANW-AMC) was measured
using fluorogenic substrates [28] as previously described
[26] in cell extracts from 22 ALL and 10 AML samples.
Active p65 NF-kB by ELISA
PBMCs (n = 48) were isolated from whole blood of
patients prior to bortezomib treatment and at 6 and
24 h after the first bortezomib dose. Nuclear lysates were
prepared, and active p65 NF-kB was determined by
ELISA (Active Motif, Carlsbad, CA) as previously
described [15]. NF-kB ELISA activity was performed in
triplicate and averages used for comparisons over time
and blast percentage ranged from 21 to 93 % (median
53 %) for ALL (n = 36) and from 22 to 85 % (median
52 %) for AML (n = 12).
Statistics
Correlations were calculated by determining Spearman’s
rank correlation coefficients. Statistical significance
between groups was determined by Mann-Whitney U
test. Logistic regression analysis was used to determine
whether the measured predictor variables were associ-
ated with response to therapy, both with and without
correction for leukaemia type (ALL/AML), blast per-
centages, gender, age and white blood cell count. All
statistical analyses were performed using IBM-SPSS (ver-
sion 20.0). A two-sided significance level of 0.05 was
used in all statistical analyses.
Results
Proteasome subunit expression in relapsed childhood
acute leukaemia samples
Consistent with our previous preliminary findings [10], in
this cohort of 60 relapsed ALL (46 pre-B ALL, 14 T-ALL)
and 12 relapsed AML patients, AML blasts did not differ
from pre-B ALL or T-ALL blasts in constitutive β1 sub-
unit expression (Fig. 1a) while both AML blasts and T-
ALL blasts had higher β5 subunit expression than pre-B
ALL blasts (p = 0.005 and p = 0.041, respectively; Fig. 1b;
Table 2). In this subset of samples, ALL samples had a sig-
nificantly higher blast percentage (median 84 %) than
AML samples (median 59 %) (p < 0.001). In order to de-
termine if the normal cells in the AML samples contribute
to the proteasome subunit composition, proteasome sub-
unit expression of PBMCs from healthy adult volunteers
(n = 5) were compared to pre-B ALL and AML samples
and revealed that the median constitutive β1 and β5 ex-
pression are both significantly lower in PBMCs compared
to AML patient samples (β1 p = 0.037 and β5 p = 0.002),
indicating that the normal cells in leukaemia samples do
not significantly contribute to the proteasome subunit
expression comparisons (Fig. 1a, b). In contrast, pre-B
Table 1 Patient demographics
ALL (n = 68) AML (n = 16)
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Fig. 1 Proteasome subunit protein expression in relapsed childhood ALL and AML. Comparison of a constitutive subunit β1 b and constitutive
subunit β5 expression for pre-B ALL (n = 46), T-ALL (n = 14) and AML (n = 12) patient samples and PBMCs from healthy adult volunteers (n = 5). c
The ratio of paired subunits β1i/β1. d The ratio of paired subunits β5i/β5, within each patient sample for pre-B ALL (n = 46), T-ALL (n = 14) and
AML (n = 12) patient samples. Protein expression was assessed by Western blotting and expressed as relative quantifications of subunit expression
(ratio proteasome subunit/β-actin based on loading of 15 μg total protein, normalized to CEM). The line denotes the mean. Significant p values
are noted (Mann-Whitney U test)
Table 2 Median proteasome subunit protein expression and NF-kB activity in paediatric acute leukaemia patients
β5 (range) β1 (range) β5i (range) β1i (range) β5i/β5 (range) β1i/β1 (range) NF-kB activity
ALL 0.055 (0.01–0.76) 0.05 (0.01–0.86) 0.46 (0.06–3.43) 0.24 (0.07–1.45) 8.2 (0.66–94.5) 5.2 (0.18–64.7) 128.1 (11.8–1025.7)
CR 0.045 (0.01–0.76) 0.05 (0.01–0.64) 0.47 (0.06–2.08) 0.31 (0.07–1.06) 8.55 (0.76–94.5) 6.8 (0.19–64.7) 253.5 (11.8–1022.2)
No CR 0.065 (0.01–0.56) 0.1 (0.01–0.86) 0.38 (0.13–3.43) 0.22 (0.07–1.45) 6.7 (0.66–52.5) 3.4 (0.25–27.2) 73.0 (24.5–1025.7)
Pre-B ALL 0.04 (0.01–0.76) 0.04 (0.01–0.62) 0.46 (0.06–3.43) 0.33 (0.07–1.45) 11.4 (0.66–94.5) 7.1 (0.19–64.7) 90.2 (11.8–1025.7)
CR 0.03 (0.01–0.76) 0.04 (0.01–0.62) 0.57 (0.06–2.08) 0.43 (0.07–1.06) 13.4 (0.76–94.5) 7.8 (0.19–64.7) 89.9 (11.8–1022.2)
No CR 0.06 (0.01–0.49) 0.1 (0.01–0.32) 0.42 (0.13–3.43) 0.23 (0.12–1.45) 9.0 (0.66–52.5) 4.2 (0.7–27.2) 98.9 (24.5–1025.7)
T-ALL 0.12 (0.01–0.69) 0.11 (0.01–0.86) 0.44 (0.17–1.12) 0.21 (0.07–0.58) 3.9 (0.92–28.5) 1.77 (0.25–15.9) 333.7 (35.3–625.3)
CR 0.21 (0.06–0.56) 0.1 (0.04–0.86) 0.37 (0.17–0.82) 0.11 (0.07–0.21) 1.78 (1.46–2.74) 1.1 (0.25–1.77) 393.5 (262.5–625.3)
No CR 0.1 (0.01–0.69) 0.11 (0.01–0.64) 0.46 (0.18–1.12) 0.22 (0.16–0.58) 5.2 (0.92–28.5) 2.28 (0.33–15.9) 37.9 (35.3–40.5)
AML 0.12 (0.04–1.98) 0.13 (0.03–0.88) 0.41 (0.09–1.08) 0.17 (0.1–0.64) 3.2 (0.24–23.0) 1.97 (0.11–6.4) 524.5 (35.3–1323.7)
CR 0.089 (0.04–0.21) 0.042 (0.031–0.26) 0.23 (0.09–0.92) 0.23 (0.13–0.64) 4.0 (0.45–23.0) 4.5 (2.4–6.3)a 804.1 (284.5–1323.7)
No CR 0.13 (0.05–1.98) 0.18 (0.04–0.88) 0.52 (0.22–1.1) 0.16 (0.1–0.49) 3.2 (0.24–11.1) 0.94 (0.11–3.5) 524.5 (35.3–1246.5)
Please note that Western blot data depict relative quantifications of subunit expression (ratio proteasome subunit/β-actin based on loading of 15 μg total protein,
normalized to CEM). Quantifications were based on one Western blot analysis per sample. For three patients multiple replicate quantifications of subunits could
be performed with a mean SD of <26 %. Lower limit of detection of protein bands quantification by Odyssey software; set to 0.01 AU for β5 and β1, 0.06 AU for
β5i and 0.07 AU for β1i
Pre-B ALL n = 45 patient samples for β5 and β5i, n = 43 for β1 and β1i, T-ALL n = 15 for β5 and β5i, n = 14 for β1 and β1i, AML n = 12 patient samples were used
CR complete remission
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ALL blasts had higher immunoproteasome subunit β1i
expression than AML blasts (p = 0.048), while no signifi-
cant difference was observed between ALL and AML for
the expression of immunoproteasome subunit β5i (Add-
itional file 1: Figure S1A, B). As a consequence, median
ratios of both β1i/β1 and β5i/β5 expression were signifi-
cantly higher in pre-B ALL patients than in T-ALL
patients (p = 0.002 for β1i/β1 and p = 0.013 for β5i/β5)
and in AML patients (p < 0.001 for β1i/β1 and p = 0.004
for β5i/β5 Fig. 1c, d; Table 2). Median blast percentages
did not differ between T-ALL (median 81 %) and pre-B
ALL (median 86 %).
Proteasome subunit expression correlations with
response to re-induction therapy
Next, we compared differences in proteasome protein
subunit expression between patients that attained CR vs.
no CR after the first re-induction therapy block. When
samples were subdivided by leukaemia subtype, a statis-
tically significant difference was detected in median β1i/
β1 ratios between CR (n = 4) and no CR (n = 8) in pa-
tients with AML (p = 0.028, Fig. 2a; Table 2). No signifi-
cant differences were detected for median β5i/β5 ratios,
also not within ALL subgroups (Fig. 2b, c). Median blast




Fig. 2 Ratio proteasome subunit protein expression in patients who achieved complete remission versus patients who did not, dissected
by leukaemia subtype. Ratios of immunoproteasome/constitutive proteasome protein expression in a AML patients, b pre-B ALL patients
and c T-ALL patients that achieved CR versus patients who did not achieve CR, determined by Western blot analysis after bortezomib-
containing re-induction therapy. The line denotes the mean
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CR and patients that did not attain CR. Despite the fact
that pre-treatment ratios of β5i/β5 or β1i/β1 were
related to achievement of CR, these parameters were not
strong enough to independently predict treatment
response in either univariable logistic regression analyses
or after controlling for blast percentage, leukaemia sub-
type, gender, age and white blood cell count in multi-
variable analysis (data not shown).
Proteasome catalytic activity
There was a good correlation between proteasome sub-
unit expression and catalytic activity for β5i/β5 (R = 0.503
p = 0.005, Fig. 3a). The median activity ratio of β5i/β5 dif-
fered significantly between pre-B ALL (n = 18) and AML
(n = 10) patients (p = 0.005, Fig. 3b) while the individual
subunits β5 and β5i did not differ (data not shown). In
addition to proteasome subunit expression ratios, median
β5i/β5 subunit activity ratios were not higher in patients
who reached CR (n = 14) compared to patients who did
not reach CR (n = 18) (Fig. 3c). Median blast percentages
did not differ statistically between CR patients (median
81 %) and no CR patients (median 71 %).
The effect of bortezomib treatment on NF-kB activity
We also examined NF-kB activity in leukaemia cells in
response to bortezomib-containing chemotherapy. NF-kB
activity was evaluated in PBMCs of 36 ALL patients (26
pre-B ALL and 10 T-ALL) and 12 AML patients at three
time points: T = 0, T = 6 and T = 24 h after the first borte-
zomib administration. Median pre-treatment NF-kB activ-
ity was significantly lower in pre-B ALL versus both T-
ALL patients (p = 0.001) and AML patients (p < 0.001)
(Fig. 4a, Table 2), while blast percentages were similar for
these groups. Twenty-four hours after bortezomib treat-
ment, pre-B ALL patients who attained a CR (n = 16)
displayed a significant decrease in median NF-kB activity
compared to pre-treatment levels (p = 0.006, Fig. 4b). In
contrast, pre-B ALL patients who did not attain a
complete remission (n = 10) after the first bortezomib
cycle showed unaltered NF-kB activity after bortezomib
treatment (Fig. 4c). Overall, however, changes in NF-kB
activity during treatment with bortezomib-containing
chemotherapy were not significantly associated with
achievement of post-re-induction CR.
Discussion
Recently, on the basis of an ex vivo study with acute leu-
kaemia clinical specimen at diagnosis, we provided evi-
dence that ratios of immunoproteasome subunits to
constitutive subunits correlate with sensitivity of acute
leukaemia cells to PIs [10]. The current research was set
up to validate this in a distinct, prospectively collected
sample set from patients enrolled on two COG clinical
trials, which is the first to study potential biomarkers
that may predict clinical sensitivity to bortezomib-
containing treatment regimens.
Although approved and efficacious for treatment of
MM, bortezomib treatment does not lead to response in
all MM patients due to emergence of drug resistance
[24]. Conceivably, resistance phenomena could also limit
the clinical utility of this agent in relapsed paediatric leu-
kaemia. Hence, parameters that could indicate the likeli-
hood of clinical response to PI therapy would provide a
mechanism to determine which patients are likely to
benefit from the addition of PI therapy to their re-
induction regimen. Several mechanisms have been
reported to underlie bortezomib resistance [29, 30].
Bortezomib-resistant cell lines are frequently character-
ized by mutations in the PSMB5 gene encoding the β5
subunit [27, 31]. To date, however, no PSMB5 mutations
have been found in patients clinically resistant to borte-
zomib [32–34]. Also in the current study, no PSMB5-
a b c
Fig. 3 Proteasome subunit catalytic activity in relapsed childhood ALL and AML patients. a Correlation of β5i/β5 protein expression and β5i/β5
catalytic activity ratios. b β5i/β5 catalytic activity ratios in pre-B ALL patients (n = 18) compared to T-ALL patients (n = 4) and AML patients (n =
10), and c β5i/β5 catalytic activity ratios in patients who achieved complete remission (n = 14) versus those who did not (n = 18). Closed circles
represent pre-B ALL patients, open triangles T-ALL patients and open squares AML patients. The line denotes the mean
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associated mutations in exon 2 of the gene were identi-
fied in either end of induction (n = 15) or relapse (n = 3)
samples (data not shown). This implies that, in acute
leukaemia, β5 mutations make only a minor contribu-
tion to bortezomib resistance and that other common
resistance mechanisms, such as overexpression of β5,
play a more important role [27, 29, 31, 35]. Confirming
our earlier ex vivo work in newly diagnosed patient sam-
ples [10], the current study shows that constitutive (β5
and β1) proteasome subunit expression was significantly
lower in patients with relapsed ALL vs. AML, whereas
β1i and β5i immunoproteasome subunit expression was
higher (though it did not reach significance). These
results were recently confirmed by de Bruin et al. [36],
who showed by labelling analysis of primary patient cells
that B cell ALL patients have higher immune/constitu-
tive subunit expression ratios than AML cells and T-
ALL cells. Given the significance of correlation between
the subunit expression and catalytic activity (Fig. 3a), the
subunit activity-based probes may prove useful for
examining clinical specimen. Others have also reported
that bortezomib sensitivity relates to proteasome expres-
sion. In particular, increased PSMB5 mRNA expression
was found in a myeloma patient who subsequently
developed bortezomib resistance [33]. Moreover,
bortezomib-sensitive hematologic cell lines harboured
higher immunoproteasome expression levels compared
to relatively bortezomib-resistant solid-tumour cell lines
[37]. Lastly, a higher β2/β1 + β5 activity ratio correlated
with higher bortezomib sensitivity in a cell line panel of
hematologic malignancies [38]. In a recent study, we
showed that interferon-γ-induced upregulation of immu-
noproteasome expression and concurrent constitutive
proteasome subunit downregulation in bortezomib-
resistant hematologic tumour cell lines resulted in the
sensitization for PI treatment [26]. Consistently, knock-
down of constitutive β5 in the AML cell line THP1
resulted in increased sensitivity to bortezomib [31].
NF-kB activity was evaluated by ELISA in 26 pre-B
ALL, 10 T-ALL and 12 AML samples after the first
dose of bortezomib. NF-kB is constitutively active in
the majority of ALL patients [23, 39] and AML
patients [40]. Though a significant decline in NF-kB
activity was observed in pre-B ALL patients 24 h
after the first bortezomib dose, this decline in NF-kB
activity did not correlate with bortezomib response.
Of note, Magrangeas et al. [41] found that low pre-
treatment levels of NF-kB were associated with a
higher response rate to bortezomib-based induction
in newly diagnosed MM, but we were unable to find
a similar correlation between pre-treatment NF-kB
activity and bortezomib. Overall, in our current
study, changes in NF-kB activity during treatment
with bortezomib-containing chemotherapy were not
associated with achievement of post-induction CR,
and neither pre-treatment NF-kB activity nor de-
creases in NF-kB activity after 24 h correlated with
clinical response.
This current cohort provided the first set of sam-
ples collected from patients who received bortezomib
treatment and could serve as a potential validation
cohort for our former test cohort [10]. Since the
design of this add-on study was not yet optimized
for the proteasome-based assays, there are some limi-
tations that have to be considered. First, although
only samples that contained >20 % of blasts were
used, there was a large variation in blast percentage
between samples (mean 72 % ± 23 %). To address the
impact of normal cells, we measured proteasome
subunit expression levels in normal PBMCs and
found that these had a relative minor contribution
on proteasome subunit expression in leukaemic cells
and thus did not largely influence our analyses. Not-
withstanding this fact, purification of lymphoblast/
myeloblast purification is recommended in future
follow-up studies. Another important issue is the fact
a b c
Fig. 4 Baseline NF-kB activity between ALL and AML patients and impact of bortezomib treatment. Pre-treatment NF-kB activity measurements
determined by p65-ELISA in PBMC of acute leukaemia patients comparing a NF-kB activity of pre-B ALL (n = 26), T-ALL (n = 10) and AML (n = 12)
patients, and b NF-kB activity prior to treatment compared to 6 and 24 h after bortezomib-containing chemotherapy in pre-B ALL patients that
reached CR (n = 16), and c pre-B ALL patients that did not reach CR (n = 10). The line denotes the mean
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that patients in this study were treated with combin-
ation therapy. Hence, any outcome variable is a cu-
mulative effect of all drugs, which can confound the
relation between our measurements and bortezomib
sensitivity.
Conclusions
In summary, cells of relapsed ALL patients had signifi-
cantly higher β5i/β5 and β1i/β1 proteasome subunit pro-
tein expression ratios, and lower β5 and β1 constitutive
subunit expression compared to cells of relapsed AML
patients. Interestingly, AML patients who achieved CR
after bortezomib-containing therapy had higher pre-
treatment immunoproteasome/constitutive proteasome
expression ratios compared to patients who did not
achieve CR. Further studies using purified blast popula-
tions are being conducted to confirm that higher ratios of
immuno-/constitutive proteasome in pre-treatment ALL
and AML cells are associated with an initial clinical
response to bortezomib-containing re-induction treatment.
Additional file
Additional file 1: Figure S1. Individual immunoproteasome subunit
protein expression in relapsed childhood acute leukaemia patients.
Figure S2. Proteasome subunit mRNA expression in NBM cells. Figure
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